0.0386
+0.0081
(26.56%)
May 23 - Close
OTCMKTS
data delayed by 15 mins -
Disclaimer
Currency in USD
| Range | 0.03 - 0.04 |
| 52 week | 0.02 - 0.12 |
| Open | 0.03 |
| Vol / Avg. | 15.74M/1.34M |
| Mkt cap | 27.09M |
| P/E | - |
| Div/yield | - |
| EPS | -0.03 |
| Shares | 701.82M |
| Beta | 1.78 |
| Inst. own | 0% |
Events
Jun 10, 2013
Q3 2013 Generex Biotechnology Corporation Earnings Release
Mar 28, 2013
Generex Biotechnology Corporation Annual & Special Shareholder Meeting
Mar 19, 2013
Q2 2013 Generex Biotechnology Corporation Earnings Release
|
|
Key stats and ratios
| Q4 (Oct '12) | 2012 | |
| Net profit margin | - | -33124.89% |
| Operating margin | - | -34987.96% |
| EBITD margin | - | -33106.42% |
| Return on average assets | -63.19% | -113.99% |
| Return on average equity | - | - |
| Employees | 11 | - |
| Carbon Disclosure Rating | - | - |
Address
Suite 604, 555 Richmond Street West, PO Box 200
TORONTO, ON M5V 3B1
Canada
+1-416-3642551 (Phone)
+1-647-5477104 (Fax)
TORONTO, ON M5V 3B1
Canada
+1-416-3642551 (Phone)
+1-647-5477104 (Fax)
Website links
External links
Discussion Group - Google Finance
Advertisement
Description
Generex Biotechnology Corporation is a Canada-based Company, which develops drug delivery systems and technologies for the treatment of diabetes. The Company has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity. Its buccal insulin spray product, Generex Oral-lyn is in Phase III clinical trials at several sites around the world. The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist device.
Officers and directors
| John P. Barratt | Independent Chairman of the Board | |
| Mark A Fletcher Esq | President, Chief Executive Officer, General Counsel, Director | |
| Stephen Fellows | Acting Chief Financial Officer | |
| David Brusegard Ph.D. | Chief Operating Officer, Secretary | |
| Eric von Hofe PhD | Director | |
| James H Anderson Jr,MD | Independent Director | |
| Brian T McGee | Independent Director |